Recent GLYC News
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 • Business Wire • 03/27/2024 11:00:00 AM
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 • Business Wire • 03/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:16:05 PM
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 12:00:00 PM
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 02/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:12 PM
- GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 • Business Wire • 01/04/2024 12:00:00 PM
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:19 PM
- GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia • Business Wire • 12/10/2023 05:00:00 PM
- GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference • Business Wire • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:35:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 12:31:36 PM
- GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 • Business Wire • 11/03/2023 11:00:00 AM
- Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board • PR Newswire (US) • 10/23/2023 12:30:00 PM
- GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 • Business Wire • 10/20/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:05:33 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM